Cargando…

Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type

Breakthrough SARS-CoV-2 infections have been reported in fully vaccinated individuals, in spite of the high efficacy of the currently available vaccines, proven in trials and real-world studies. Several variants of concern (VOC) have been proffered to be associated with breakthrough infections follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dingemans, Jozef, van der Veer, Brian M. J. W., Gorgels, Koen M. F., Hackert, Volker, den Heijer, Casper D. J., Hoebe, Christian J. P. A, Savelkoul, Paul H. M., van Alphen, Lieke B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729533/
https://www.ncbi.nlm.nih.gov/pubmed/36504818
http://dx.doi.org/10.3389/fmicb.2022.1027271
_version_ 1784845488159195136
author Dingemans, Jozef
van der Veer, Brian M. J. W.
Gorgels, Koen M. F.
Hackert, Volker
den Heijer, Casper D. J.
Hoebe, Christian J. P. A
Savelkoul, Paul H. M.
van Alphen, Lieke B.
author_facet Dingemans, Jozef
van der Veer, Brian M. J. W.
Gorgels, Koen M. F.
Hackert, Volker
den Heijer, Casper D. J.
Hoebe, Christian J. P. A
Savelkoul, Paul H. M.
van Alphen, Lieke B.
author_sort Dingemans, Jozef
collection PubMed
description Breakthrough SARS-CoV-2 infections have been reported in fully vaccinated individuals, in spite of the high efficacy of the currently available vaccines, proven in trials and real-world studies. Several variants of concern (VOC) have been proffered to be associated with breakthrough infections following immunization. In this study, we investigated 378 breakthrough infections recorded between January and July 2021 and compared the distribution of SARS-CoV-2 genotypes identified in 225 fully vaccinated individuals to the frequency of circulating community lineages in the region of South Limburg (The Netherlands) in a week-by-week comparison. Although the proportion of breakthrough infections was relatively low and stable when the Alpha variant was predominant, the rapid emergence of the Delta variant lead to a strong increase in breakthrough infections, with a higher relative proportion of individuals vaccinated with Vaxzevria or Jcovden being infected compared to those immunized with mRNA-based vaccines. A significant difference in median age was observed when comparing fully vaccinated individuals with severe symptoms (83 years) to asymptomatic cases (46.5 years) or individuals with mild-to-moderate symptoms (42 years). There was no association between SARS-CoV-2 genotype or vaccine type and disease symptoms. Furthermore, the majority of adaptive mutations were concentrated in the N-terminal domain of the Spike protein, highlighting its role in immune evasion. Interestingly, symptomatic individuals harbored significantly higher SARS-CoV-2 loads than asymptomatic vaccinated individuals and breakthrough infections caused by the Delta variant were associated with increased viral loads compared to those caused by the Alpha variant. In addition, we investigated the role of the Omicron variant in causing breakthrough infections by analyzing 135 samples that were randomly selected for genomic surveillance during the transition period from Delta to Omicron. We found that the proportion of Omicron vs. Delta infections was significantly higher in individuals who received a booster vaccine compared to both unvaccinated and fully vaccinated individuals. Altogether, these results indicate that the emergence of the Delta variant and in particular Omicron has lowered the efficiency of particular vaccine types to prevent SARS-CoV-2 infections and that, although rare, the elderly are particularly at risk of becoming severely infected as the consequence of a breakthrough infection.
format Online
Article
Text
id pubmed-9729533
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97295332022-12-09 Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type Dingemans, Jozef van der Veer, Brian M. J. W. Gorgels, Koen M. F. Hackert, Volker den Heijer, Casper D. J. Hoebe, Christian J. P. A Savelkoul, Paul H. M. van Alphen, Lieke B. Front Microbiol Microbiology Breakthrough SARS-CoV-2 infections have been reported in fully vaccinated individuals, in spite of the high efficacy of the currently available vaccines, proven in trials and real-world studies. Several variants of concern (VOC) have been proffered to be associated with breakthrough infections following immunization. In this study, we investigated 378 breakthrough infections recorded between January and July 2021 and compared the distribution of SARS-CoV-2 genotypes identified in 225 fully vaccinated individuals to the frequency of circulating community lineages in the region of South Limburg (The Netherlands) in a week-by-week comparison. Although the proportion of breakthrough infections was relatively low and stable when the Alpha variant was predominant, the rapid emergence of the Delta variant lead to a strong increase in breakthrough infections, with a higher relative proportion of individuals vaccinated with Vaxzevria or Jcovden being infected compared to those immunized with mRNA-based vaccines. A significant difference in median age was observed when comparing fully vaccinated individuals with severe symptoms (83 years) to asymptomatic cases (46.5 years) or individuals with mild-to-moderate symptoms (42 years). There was no association between SARS-CoV-2 genotype or vaccine type and disease symptoms. Furthermore, the majority of adaptive mutations were concentrated in the N-terminal domain of the Spike protein, highlighting its role in immune evasion. Interestingly, symptomatic individuals harbored significantly higher SARS-CoV-2 loads than asymptomatic vaccinated individuals and breakthrough infections caused by the Delta variant were associated with increased viral loads compared to those caused by the Alpha variant. In addition, we investigated the role of the Omicron variant in causing breakthrough infections by analyzing 135 samples that were randomly selected for genomic surveillance during the transition period from Delta to Omicron. We found that the proportion of Omicron vs. Delta infections was significantly higher in individuals who received a booster vaccine compared to both unvaccinated and fully vaccinated individuals. Altogether, these results indicate that the emergence of the Delta variant and in particular Omicron has lowered the efficiency of particular vaccine types to prevent SARS-CoV-2 infections and that, although rare, the elderly are particularly at risk of becoming severely infected as the consequence of a breakthrough infection. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9729533/ /pubmed/36504818 http://dx.doi.org/10.3389/fmicb.2022.1027271 Text en Copyright © 2022 Dingemans, van der Veer, Gorgels, Hackert, den Heijer, Hoebe, Savelkoul and van Alphen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Dingemans, Jozef
van der Veer, Brian M. J. W.
Gorgels, Koen M. F.
Hackert, Volker
den Heijer, Casper D. J.
Hoebe, Christian J. P. A
Savelkoul, Paul H. M.
van Alphen, Lieke B.
Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
title Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
title_full Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
title_fullStr Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
title_full_unstemmed Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
title_short Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
title_sort investigating sars-cov-2 breakthrough infections per variant and vaccine type
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729533/
https://www.ncbi.nlm.nih.gov/pubmed/36504818
http://dx.doi.org/10.3389/fmicb.2022.1027271
work_keys_str_mv AT dingemansjozef investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT vanderveerbrianmjw investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT gorgelskoenmf investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT hackertvolker investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT denheijercasperdj investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT hoebechristianjpa investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT savelkoulpaulhm investigatingsarscov2breakthroughinfectionspervariantandvaccinetype
AT vanalphenliekeb investigatingsarscov2breakthroughinfectionspervariantandvaccinetype